Skip to content
Screener

Ultragenyx Pharmaceutical RARE Q4 2025 Annual earnings

Reported February 12, 2026 · After market close

Revenue$207.0MBeat by $8.4M
EPS-$1.29Miss by $0.09
Revenue estimate$198.6M
EPS estimate-$1.20

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$182.9M
EPS estimate-$0.65

Financials

Q4 2025

Income statement

See full
Revenue$207.3M+25.9%
Operating income-$113.3M+7.4%
Net income-$128.6M+3.5%
EPS (diluted)-$1.28+7.2%

Balance sheet

See full
Cash & equivalents$421.0M+142%
Total debt$36.0M-10.8%
Total equity-$80.0M-131%
Total assets$1.5B+1.9%

Cash flow

See full
Operating cash flow-$99.8M-25.9%
CapEx$938.0K+475%
Free cash flow-$100.8M-26.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.22B-42.9%
Enterprise value$1.83B-51.1%
P/S3.3×-3.6×

Profitability

See full
Operating margin-79.5%-11.5pp
Net margin-85.4%-11.7pp
FCF margin-70.1%-4.4pp

Returns & leverage

See full
Current ratio2.5×+0.1×

Segments

By geography

See full
North America$132.7M+13.9%
Latin America$38.8M+106%
EMEA$30.4M+18.5%
Asia Pacific$5.4M+47.3%

By product

See full
Collaboration And Royalty$145.8M+25.8%
Royalty$105.6M+13.3%
Non Cash Royalty$37.6M+11.9%

FAQ

When did Ultragenyx Pharmaceutical report Q4 2025 earnings?
Ultragenyx Pharmaceutical (RARE) reported Q4 2025 earnings on February 12, 2026 after market close.
What were Ultragenyx Pharmaceutical's Q4 2025 revenue and EPS?
Ultragenyx Pharmaceutical reported revenue of $207.0M and eps of $-1.29 for Q4 2025.
Did Ultragenyx Pharmaceutical beat estimates in Q4 2025?
Revenue beat the consensus estimate of $198.6M by $8.4M. EPS missed the consensus estimate of $-1.20 by $0.09.
How did Ultragenyx Pharmaceutical's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 25.5% from $164.9M a year earlier and eps grew 7.2% from $-1.39.
Where can I find Ultragenyx Pharmaceutical's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-048738) and the 10-K periodic report (0001193125-26-057329) directly on SEC EDGAR. The filing index links above go to sec.gov.